| Melissa Dye, LCSW | |
|
406 W Main St Ste 100, Abingdon, VA 24210-2608 | |
| (276) 356-0501 | |
| Not Available |
| Full Name | Melissa Dye |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 13 Years |
| Location | 406 W Main St Ste 100, Abingdon, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881092211 | NPI | - | NPPES |
| 7680 | Other | TN | STATE LICENSE |
| 0904008805 | Other | VA | STATE LICENSE |
| 6094 | Other | SD | STATE LICENSE |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hardin County Regional Health Center | 3779490776 | 27 |
| Hardin County Regional Health Center | 3779490776 | 27 |
| Henry County Medical Center | 6002898665 | 47 |
News Archive
In today's health policy headlines, more speculation about how the new health law could be impacted by the midterm congressional elections.
Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009.
Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
New research presented today at the World Congress Summit to Improve Adherence and Enhance Patient Engagement by researchers from the University of Pittsburgh School of Pharmacy, finds that a unique generic medication sampling program, the MedVantx MedStart™ Connect program, implemented in the primary care physicians' office, led to significantly increased patient initiation of new prescriptions (primary adherence) as well as continued use of the medications (secondary adherence), and could possibly lead to savings for health plans.
› Verified 3 days ago
| Entity Name | Heatherwood Counseling Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780614594 PECOS PAC ID: 9133100605 Enrollment ID: O20040528001201 |
News Archive
In today's health policy headlines, more speculation about how the new health law could be impacted by the midterm congressional elections.
Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009.
Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
New research presented today at the World Congress Summit to Improve Adherence and Enhance Patient Engagement by researchers from the University of Pittsburgh School of Pharmacy, finds that a unique generic medication sampling program, the MedVantx MedStart™ Connect program, implemented in the primary care physicians' office, led to significantly increased patient initiation of new prescriptions (primary adherence) as well as continued use of the medications (secondary adherence), and could possibly lead to savings for health plans.
› Verified 3 days ago
| Entity Name | Savida Health, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548739170 PECOS PAC ID: 4082809967 Enrollment ID: O20190426001267 |
News Archive
In today's health policy headlines, more speculation about how the new health law could be impacted by the midterm congressional elections.
Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009.
Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
New research presented today at the World Congress Summit to Improve Adherence and Enhance Patient Engagement by researchers from the University of Pittsburgh School of Pharmacy, finds that a unique generic medication sampling program, the MedVantx MedStart™ Connect program, implemented in the primary care physicians' office, led to significantly increased patient initiation of new prescriptions (primary adherence) as well as continued use of the medications (secondary adherence), and could possibly lead to savings for health plans.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Dye, LCSW 17305 Rich Valley Rd, Abingdon, VA 24210-2111 Ph: (276) 608-1744 | Melissa Dye, LCSW 406 W Main St Ste 100, Abingdon, VA 24210-2608 Ph: (276) 356-0501 |
News Archive
In today's health policy headlines, more speculation about how the new health law could be impacted by the midterm congressional elections.
Cynosure, Inc., a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three and 12 months ended December 31, 2009.
Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
New research presented today at the World Congress Summit to Improve Adherence and Enhance Patient Engagement by researchers from the University of Pittsburgh School of Pharmacy, finds that a unique generic medication sampling program, the MedVantx MedStart™ Connect program, implemented in the primary care physicians' office, led to significantly increased patient initiation of new prescriptions (primary adherence) as well as continued use of the medications (secondary adherence), and could possibly lead to savings for health plans.
› Verified 3 days ago
Lynn Heath Rasnake, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 610 Campus Dr, Abingdon, VA 24210 Phone: 276-525-1587 Fax: 276-525-1609 | |
Jennifer Lenore Blankenship, L.C.S.W. Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 335 E Main St, Abingdon, VA 24210 Phone: 276-628-2510 Fax: 276-628-9594 | |
Carolyn Peterson, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 610 Campus Dr, Abingdon, VA 24210 Phone: 276-525-1587 Fax: 276-525-1609 | |
Matthew Vincent Verlander, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 610 Campus Dr, Abingdon, VA 24210 Phone: 276-525-1550 Fax: 276-525-1609 | |
Mallory Morphew Jessee, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 610 Campus Dr, Abingdon, VA 24210 Phone: 276-525-1587 Fax: 276-525-1609 | |
Mrs. Heather Green, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 661 E Main St, Abingdon, VA 24210 Phone: 276-623-9245 | |
Janan F Hurst, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 460 W Main St, Abingdon, VA 24210 Phone: 276-628-5752 Fax: 276-628-5190 |